Combining either anti‐TGFβ antibody or antagotRF‐22 with anti‐PD‐1 antibody resulted in a significant decrease in PMN‐MDSCs, an increase in CD8+ T cells, and a dramatic impairment in tumor growth. Here, CD8A is linked to neoplasm.